Plasma metabolic profiling implicates dysregulated lipid metabolism and glycolytic shift in hyperinflammatory ARDS.
ARDS
latent class analysis
metabolomics
phenotyping
precision medicine
Journal
American journal of physiology. Lung cellular and molecular physiology
ISSN: 1522-1504
Titre abrégé: Am J Physiol Lung Cell Mol Physiol
Pays: United States
ID NLM: 100901229
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
pmc-release:
01
03
2024
pubmed:
18
1
2023
medline:
9
3
2023
entrez:
17
1
2023
Statut:
ppublish
Résumé
Using latent class analysis (LCA) of clinical and protein biomarkers, researchers have identified two phenotypes of the acute respiratory distress syndrome (ARDS) with divergent clinical trajectories and treatment responses. We investigated whether plasma metabolites differed among patients with LCA-derived hyperinflammatory and hypoinflammatory ARDS, and we tested the prognostic utility of adding metabolic clusters to LCA phenotypes. We analyzed data from 93 patients with ARDS and sepsis enrolled in a multicenter prospective cohort of critically ill patients, comparing 970 metabolites between the two LCA-derived phenotypes. In all, 188 metabolites were differentially abundant between the two LCA-derived phenotypes. After adjusting for age, sex, confounding medications, and comorbid liver and kidney disease, 82 metabolites remained significantly different. Patients with hyperinflammatory ARDS had reduced circulating lipids but high levels of pyruvate, lactate, and malate. Metabolic cluster and LCA-derived phenotypes were each significantly and independently associated with survival. Patients with hyperinflammatory ARDS may be experiencing a glycolytic shift leading to dysregulated lipid metabolism. Metabolic profiling offers prognostic information beyond what is captured by LCA phenotypes alone. Deeper biological profiling may identify key differences in pathogenesis among patients with ARDS and may lead to novel targeted therapies.
Identifiants
pubmed: 36648136
doi: 10.1152/ajplung.00278.2022
pmc: PMC9988532
doi:
Substances chimiques
Biomarkers
0
Banques de données
figshare
['10.6084/m9.figshare.21741350', '10.6084/m9.figshare.21741353', '10.6084/m9.figshare.21737525', '10.6084/m9.figshare.21737576', '10.6084/m9.figshare.21739112', '10.6084/m9.figshare.21739115']
Types de publication
Multicenter Study
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
L297-L306Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL152083
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL140026
Pays : United States
Références
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W652-60
pubmed: 19429898
PLoS Med. 2013 Dec;10(12):e1001577; discussion e1001577
pubmed: 24391478
Biochim Biophys Acta. 2006 Oct;1761(10):1200-12
pubmed: 17023202
Lancet Respir Med. 2020 Mar;8(3):247-257
pubmed: 31948926
N Engl J Med. 2014 Jun 5;370(23):2191-200
pubmed: 24835849
Intensive Care Med. 2014 Apr;40(4):504-12
pubmed: 24556914
Crit Care. 2018 Dec 29;22(1):360
pubmed: 30594224
Eur J Anaesthesiol. 2022 Jun 1;39(6):521-532
pubmed: 34534172
Thorax. 2022 Jan;77(1):13-21
pubmed: 34253679
Am J Physiol Lung Cell Mol Physiol. 2017 May 1;312(5):L703-L709
pubmed: 28258106
Nat Rev Immunol. 2008 May;8(5):349-61
pubmed: 18437155
Am J Respir Crit Care Med. 2011 Sep 15;184(6):647-55
pubmed: 21680948
N Engl J Med. 2000 May 4;342(18):1301-8
pubmed: 10793162
N Engl J Med. 2006 Jun 15;354(24):2564-75
pubmed: 16714767
Am J Respir Crit Care Med. 2017 Feb 1;195(3):331-338
pubmed: 27513822
Am J Respir Crit Care Med. 2013 Apr 1;187(7):736-42
pubmed: 23328529
Curr Pharm Biotechnol. 2006 Dec;7(6):467-82
pubmed: 17168664
Biomed Res Int. 2015;2015:653750
pubmed: 26339627
Lancet Respir Med. 2018 Sep;6(9):691-698
pubmed: 30078618
N Engl J Med. 2004 Jul 22;351(4):327-36
pubmed: 15269312
Am J Physiol Lung Cell Mol Physiol. 2021 Dec 1;321(6):L1067-L1068
pubmed: 34668417
Sci Transl Med. 2013 Jul 24;5(195):195ra95
pubmed: 23884467
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nucleic Acids Res. 2021 Jul 2;49(W1):W388-W396
pubmed: 34019663
Biochim Biophys Acta. 2014 Sep;1842(9):1579-86
pubmed: 24905734
Am J Physiol Lung Cell Mol Physiol. 2021 Jul 1;321(1):L79-L90
pubmed: 33949201
J Clin Invest. 1990 Sep;86(3):696-702
pubmed: 2394827
Lancet Respir Med. 2014 Aug;2(8):611-20
pubmed: 24853585
Crit Care Explor. 2021 Jul 29;3(8):e0478
pubmed: 34345827
Crit Care Explor. 2020 Oct 12;2(10):e0241
pubmed: 33134939
Intensive Care Med. 2012 Oct;38(10):1573-82
pubmed: 22926653
Crit Care Explor. 2022 Mar 28;4(4):e0663
pubmed: 35372847
Intensive Care Med. 2018 Nov;44(11):1859-1869
pubmed: 30291376
JCI Insight. 2019 Feb 7;4(3):
pubmed: 30728333
Crit Care. 2003 Dec;7(6):413-4
pubmed: 14624677
Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):818-24
pubmed: 7509706
PLoS One. 2014 Jan 30;9(1):e87538
pubmed: 24498130
Nat Protoc. 2022 Aug;17(8):1735-1761
pubmed: 35715522
Intensive Care Med. 2020 Jun;46(6):1222-1231
pubmed: 32206845
Lipids. 2004 Dec;39(12):1147-61
pubmed: 15736910
Lancet Respir Med. 2021 Aug;9(8):933-936
pubmed: 33915103
Crit Care Med. 1997 Jul;25(7):1198-206
pubmed: 9233748
Respir Res. 2018 Apr 10;19(1):60
pubmed: 29636049
Crit Care Med. 2021 Jan 1;49(1):e63-e79
pubmed: 33165028
Physiol Rev. 2018 Jul 1;98(3):1335-1370
pubmed: 29717929
Am J Respir Crit Care Med. 2019 Jul 1;200(1):42-50
pubmed: 30645145
N Engl J Med. 2014 Oct 30;371(18):1695-703
pubmed: 25268516
Nature. 2010 Mar 4;464(7285):104-7
pubmed: 20203610